Osimertinib Dose Escalation Induces Regression of Progressive EGFR T790M-Mutant Leptomeningeal Lung Adenocarcinoma

J Thorac Oncol. 2017 Nov;12(11):e188-e190. doi: 10.1016/j.jtho.2017.07.029.

Authors

Christine Cordova¹, Andrew S Chi², Abraham Chachoua¹, Douglas Kondziolka³, Joshua S Silverman⁴, Timothy M Shepherd⁵, Rajan Jain⁵, Matija Snuderl⁶

Affiliations

¹ Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, New York.
² Laura and Isaac Perlmutter Cancer Center, New York University School of Medicine, New York, New York. Electronic address: [email protected].
³ Department of Neurosurgery, New York University School of Medicine, New York, New York.
⁴ Department of Radiation Oncology, New York University School of Medicine, New York, New York.
⁵ Division of Neuroradiology, Department of Radiology, New York University School of Medicine, New York, New York.
⁶ Division of Molecular Pathology, Department of Pathology, New York University School of Medicine, New York, New York.

PMID: 29074213
DOI: 10.1016/j.jtho.2017.07.029

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Acrylamides
Adenocarcinoma / drug therapy*
Adenocarcinoma / pathology
Adenocarcinoma of Lung
Aged
Aniline Compounds
ErbB Receptors / metabolism*
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology
Piperazines / pharmacology
Piperazines / therapeutic use*
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use*

Substances

Acrylamides
Aniline Compounds
Piperazines
Protein Kinase Inhibitors
osimertinib
ErbB Receptors